Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

NCT05841849 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

1028

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG: Aprepitant
DRUG: Palonosetron
DRUG: Fosaprepitant

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University